[go: up one dir, main page]

WO2010048149A3 - Heterocyclic modulators of gpr119 for treatment of disease - Google Patents

Heterocyclic modulators of gpr119 for treatment of disease Download PDF

Info

Publication number
WO2010048149A3
WO2010048149A3 PCT/US2009/061281 US2009061281W WO2010048149A3 WO 2010048149 A3 WO2010048149 A3 WO 2010048149A3 US 2009061281 W US2009061281 W US 2009061281W WO 2010048149 A3 WO2010048149 A3 WO 2010048149A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
gpr119
disease
heterocyclic modulators
modulators
Prior art date
Application number
PCT/US2009/061281
Other languages
French (fr)
Other versions
WO2010048149A2 (en
Inventor
Nicholas D. Smith
Celine Bonnefous
Mehmet Kahraman
Stewart A. Noble
Joseph E. Payne
Steven P. Govek
Original Assignee
Kalypsys, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalypsys, Inc. filed Critical Kalypsys, Inc.
Publication of WO2010048149A2 publication Critical patent/WO2010048149A2/en
Publication of WO2010048149A3 publication Critical patent/WO2010048149A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Disclosed herein are compounds and methods which may be useful as inhibitors of GPR 119 for the treatment or prevention of diseases including cardiovascular and metabolic diseases.
PCT/US2009/061281 2008-10-20 2009-10-20 Heterocyclic modulators of gpr119 for treatment of disease WO2010048149A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10663808P 2008-10-20 2008-10-20
US61/106,638 2008-10-20
US14385409P 2009-01-12 2009-01-12
US61/143,854 2009-01-12
US15411509P 2009-02-20 2009-02-20
US61/154,115 2009-02-20

Publications (2)

Publication Number Publication Date
WO2010048149A2 WO2010048149A2 (en) 2010-04-29
WO2010048149A3 true WO2010048149A3 (en) 2010-09-02

Family

ID=42119931

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/061281 WO2010048149A2 (en) 2008-10-20 2009-10-20 Heterocyclic modulators of gpr119 for treatment of disease

Country Status (1)

Country Link
WO (1) WO2010048149A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940748B2 (en) 2009-10-08 2015-01-27 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9012462B2 (en) 2008-05-21 2015-04-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
JP5489997B2 (en) 2007-07-19 2014-05-14 シマベイ セラピューティクス， インコーポレーテッド N-aza cyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of RUP3 or GPRl 19 receptors for the treatment of diabetes and metabolic diseases
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
WO2010008739A2 (en) * 2008-06-20 2010-01-21 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
WO2010149685A1 (en) 2009-06-24 2010-12-29 Boehringer Ingelheim International Gmbh New compounds, pharmaceutical composition and methods relating thereto
AU2010264720A1 (en) 2009-06-24 2011-12-08 Boehringer Ingelheim International Gmbh New compounds, pharmaceutical composition and methods relating thereto
CA2775840C (en) 2009-10-01 2018-02-06 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
WO2011044184A1 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
EP2485591B1 (en) 2009-10-08 2016-03-23 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2011044185A2 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
AU2010311511B2 (en) 2009-10-30 2014-07-17 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors
US8486967B2 (en) * 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
AR080754A1 (en) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv IMIDAZO DERIVATIVES (1,2-A) PIRAZINA AND ITS USE AS PDE10 INHIBITORS
JP2013522279A (en) 2010-03-18 2013-06-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination of GPR119 agonist and DDP-IV inhibitor linagliptin for use in the treatment of diabetes and related conditions
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
NZ734535A (en) 2010-04-22 2019-05-31 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
CN109674753A (en) 2010-06-23 2019-04-26 希玛贝治疗股份有限公司 Solid dispersion
UA112517C2 (en) 2010-07-06 2016-09-26 Новартіс Аг TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES
WO2012006955A1 (en) * 2010-07-14 2012-01-19 Zhejiang Beta Pharma Inc. Compounds for treatment of metabolic disorders
PH12013500671A1 (en) 2010-10-08 2018-04-11 Cadila Healthcare Ltd Novel gpr 119 agonists
ES2577027T3 (en) 2010-12-03 2016-07-12 Epizyme, Inc. Purine and 7-desazapurinic compounds substituted as epigenetic enzyme modulators
AU2011336272A1 (en) 2010-12-03 2013-06-20 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
US20120184572A1 (en) * 2011-01-13 2012-07-19 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
EP2686312B1 (en) * 2011-03-14 2016-08-31 Boehringer Ingelheim International GmbH N-cyclopropyl-n-piperidinylbenzamides as gpr119 modulators
CA2831582C (en) 2011-03-28 2019-01-08 Mei Pharma, Inc. (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
CN103702989B (en) 2011-05-04 2017-07-07 理森制药股份公司 As the compounds of protein kinase modulators
MX360404B (en) 2011-05-04 2018-10-31 Ariad Pharma Inc Compounds for inhibiting cell proliferation in egfr-driven cancers.
CA2838645C (en) 2011-06-27 2020-03-10 Janssen Pharmaceutica Nv 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
AR087701A1 (en) 2011-08-31 2014-04-09 Japan Tobacco Inc PIRAZOL DERIVATIVES WITH SGLT1 INHIBITING ACTIVITY
WO2013157022A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
PL3459942T3 (en) 2012-04-24 2021-10-11 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
JP6469567B2 (en) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Compound for inhibiting cell proliferation of EGFR-activated cancer
DK2858986T3 (en) * 2012-06-12 2019-11-25 Chong Kun Dang Pharmaceutical Corp PIPERIDE INGREDIENTS AS GPR119 AGONISTS
US9669035B2 (en) 2012-06-26 2017-06-06 Janssen Pharmaceutica Nv Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl-[1,2,4]triazolo-[4,3-A]]quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological of metabolic disorders
EP2869822B1 (en) 2012-07-09 2016-09-14 Janssen Pharmaceutica, N.V. Inhibitors of phosphodiesterase 10 enzyme
AR091739A1 (en) 2012-07-11 2015-02-25 Elcelyx Therapeutics Inc COMPOSITIONS AND METHODS TO REDUCE CARDIOMETABOLIC RISK
US20150284422A1 (en) 2012-08-10 2015-10-08 Epizyme, Inc. Inhibitors of protein methyltransferase dot1l and methods of use thereof
AU2013312319B2 (en) 2012-09-06 2018-04-19 Epizyme, Inc. Method of treating leukemia
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
AR092924A1 (en) 2012-10-09 2015-05-06 Sanofi Sa PIRROLIDINONE DERIVATIVES AS MODULATORS OF GPR119 FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
JP6360878B2 (en) 2013-03-12 2018-07-18 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ DNA-PK inhibitor
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
SG10201802911RA (en) 2013-03-15 2018-05-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9738679B2 (en) 2013-03-15 2017-08-22 Epizyme, Inc. Methods of synthesizing substituted purine compounds
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
BR112015026631A2 (en) * 2013-04-25 2017-07-25 Yuhan Corp pharmaceutically acceptable compounds or salts thereof and their uses, pharmaceutical composition and method for preventing or treating mammalian diabetes mellitus
DE102013008118A1 (en) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
DK3013796T3 (en) * 2013-06-27 2020-03-16 Lg Chemical Ltd BIARLDER DERIVATIVES AS GPR120 AGONISTS
GB201314452D0 (en) 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
MX363708B (en) 2013-10-14 2019-03-29 Eisai R&D Man Co Ltd Selectively substituted quinoline compounds.
JP6223563B2 (en) 2013-10-14 2017-11-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 Selectively substituted quinoline compounds
EP3057953B1 (en) 2013-10-17 2018-08-15 Vertex Pharmaceuticals Incorporated Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors
EA202092627A1 (en) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
MX366297B (en) 2013-11-26 2019-07-04 Chong Kun Dang Pharmaceutical Corp Amide derivatives for gpr119 agonist.
MX2016008131A (en) 2013-12-20 2016-09-16 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy.
KR20160100408A (en) * 2014-01-06 2016-08-23 리젠 파마슈티컬스 소시에떼 아노님 Novel glutaminase inhibitors
JO3517B1 (en) 2014-01-17 2020-07-05 Novartis Ag N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2
JP6523303B2 (en) 2014-01-17 2019-05-29 ノバルティス アーゲー 1-Pyridazin / triazin-3-yl-piperazine / piperidine / pyrrolidine derivatives for inhibiting the activity of SHP2 and compositions thereof
CN105899493B (en) 2014-01-17 2019-03-29 诺华股份有限公司 For inhibiting the active 1- of SHP2 (triazine -3- base/pyridazine -3- base)-piperazine (- piperazine) piperidine derivatives and combinations thereof
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9493442B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
SG10201806849WA (en) 2014-02-13 2018-09-27 Incyte Corp Cyclopropylamines as lsd1 inhibitors
LT3105226T (en) 2014-02-13 2019-11-11 Incyte Corp CYCLOPROPILAMINES AS LSD1 INHIBITORS
AR099936A1 (en) 2014-04-04 2016-08-31 Sanofi Sa CONDENSED HETEROCICLES REPLACED AS MODULATORS OF GPR119 FOR THE TREATMENT OF DIABETES, OBESITY, DISLIPIDEMIA AND RELATED DISORDERS
TW201623286A (en) 2014-04-04 2016-07-01 賽諾菲公司 Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
KR20160132887A (en) 2014-04-04 2016-11-21 사노피 Substituted indanone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
RU2744460C2 (en) 2014-04-15 2021-03-09 Вертекс Фармасьютикалз Инкорпорейтед Pharmaceutical compositions for treating diseases mediated by cystic fibrosis transmembrane conductance regulator
US9902730B2 (en) 2014-05-01 2018-02-27 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
EP3137468B1 (en) 2014-05-01 2021-10-06 Novartis AG Compounds and compositions as toll-like receptor 7 agonists
WO2015170218A1 (en) 2014-05-07 2015-11-12 Pfizer Inc. Tropomyosin-related kinase inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
UY36294A (en) 2014-09-12 2016-04-29 Novartis Ag COMPOUNDS AND COMPOSITIONS AS QUINASA INHIBITORS
DK3193611T3 (en) 2014-09-17 2021-05-10 Celgene Car Llc MK2 INHIBITORS AND USES THEREOF
GB201501302D0 (en) 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
WO2016205590A1 (en) 2015-06-18 2016-12-22 Cephalon, Inc. Substituted 4-benzyl and 4-benzoyl piperidine derivatives
MX2017016669A (en) 2015-06-18 2018-04-13 Cephalon Inc 1, 4-substituted piperidine derivatives.
CN112625028B (en) 2015-06-19 2024-10-29 诺华股份有限公司 Compounds and compositions for inhibiting SHP2 activity
US10308660B2 (en) 2015-06-19 2019-06-04 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
US10975080B2 (en) 2015-06-19 2021-04-13 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
EA035534B1 (en) 2015-08-12 2020-06-30 Инсайт Корпорейшн Salts of an lsd1 inhibitor
GB201517523D0 (en) 2015-10-05 2015-11-18 Ostara Biomedical Ltd Methods and compositions for managing reproduction
MA44334A (en) 2015-10-29 2018-09-05 Novartis Ag ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST
CN109414410B (en) 2016-04-22 2022-08-12 因赛特公司 Formulations of LSD1inhibitors
CA3026149A1 (en) 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
JP7051829B2 (en) 2016-06-13 2022-04-11 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Substituted pyridine as an inhibitor of DNMT1
PT3468972T (en) 2016-06-14 2020-08-21 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
EP3493807A1 (en) 2016-08-03 2019-06-12 CymaBay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
WO2018064092A1 (en) 2016-09-27 2018-04-05 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors
US20190343836A1 (en) 2017-01-10 2019-11-14 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
SI3571193T1 (en) 2017-01-23 2022-04-29 Cadent Therapeutics, Inc. Potassium channel modulators
US10392366B2 (en) 2017-02-21 2019-08-27 Sanofi Azetidine compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
PT3618875T (en) 2017-05-02 2023-08-07 Novartis Ag Combination therapy
KR20240097982A (en) 2017-05-23 2024-06-27 메이 파마, 아이엔씨. Combination therapy
EP3651752B1 (en) 2017-07-11 2024-11-20 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
EP3668507A4 (en) 2017-08-14 2021-05-12 MEI Pharma, Inc. Combination therapy
JP2020536863A (en) 2017-10-06 2020-12-17 フォーマ セラピューティクス，インコーポレイテッド Ubiquitin-specific inhibition of peptidase 30
BR112020019191A2 (en) 2018-03-23 2021-01-05 Yumanity Therapeutics, Inc. COMPOUNDS AND THEIR USES
AU2019271279A1 (en) 2018-05-17 2020-11-26 Forma Therapeutics, Inc. Fused bicyclic compounds useful as Ubiquitin-Specific Peptidase 30 inhibitors
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
US11459340B2 (en) 2018-09-18 2022-10-04 Nikang Therapeutics, Inc. Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors
SMT202300164T1 (en) 2018-10-05 2023-07-20 Forma Therapeutics Inc Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors
US11993586B2 (en) 2018-10-22 2024-05-28 Novartis Ag Crystalline forms of potassium channel modulators
RS64828B1 (en) 2018-11-06 2023-12-29 Edgewise Therapeutics Inc Pyridazinone compounds and uses thereof
US11603523B2 (en) 2019-01-18 2023-03-14 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
JP2022520930A (en) 2019-01-24 2022-04-04 ユマニティ セラピューティクス，インコーポレーテッド Compounds and their use
AU2020276695A1 (en) 2019-05-13 2021-12-23 Novartis Ag New crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as Raf inhibitors for the treatment of cancer
AR119731A1 (en) 2019-05-17 2022-01-05 Novartis Ag NLRP3 INFLAMASOME INHIBITORS
WO2021004467A1 (en) * 2019-07-08 2021-01-14 南京明德新药研发有限公司 Compound as porcupine inhibitor and use thereof
RS66307B1 (en) 2019-12-06 2025-01-31 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
JP2023526625A (en) 2020-05-19 2023-06-22 キャリーオペ，インク． AMPK Activator
AU2021297323A1 (en) 2020-06-26 2023-02-16 Kallyope, Inc. AMPK activators
US20240109865A1 (en) 2020-12-30 2024-04-04 Tyra Biosciences, Inc. Indazole compounds as kinase inhibitors
MX2023009682A (en) 2021-02-19 2023-10-30 Sudo Biosciences Ltd Tyk2 inhibitors and uses thereof.
WO2022175752A1 (en) 2021-02-19 2022-08-25 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
PE20241335A1 (en) 2021-06-04 2024-07-03 Vertex Pharma N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS SODIUM CHANNEL MODULATORS
JP2024529118A (en) * 2021-08-13 2024-08-01 アセンテージ ファーマ（スーチョウ）カンパニー，リミティド Methods for Treating Disease or Disorders
CN113480522A (en) * 2021-08-19 2021-10-08 守恒(厦门)医疗科技有限公司 Novel phenylpyrazole derivative and application thereof in hypoglycemic drugs
AR127064A1 (en) 2021-09-15 2023-12-13 Hua Medicine Shanghai Ltd PRODRUGS OF PYRROLIDONE DERIVATIVES AS A GLUCOKINASE ACTIVATOR

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070562A1 (en) * 2003-07-11 2005-03-31 Jones Robert M. Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2005121121A2 (en) * 2004-06-04 2005-12-22 Arena Pharmaceuticals, Inc. Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20080058339A1 (en) * 2006-08-30 2008-03-06 Biovitrum New compounds
WO2008070692A2 (en) * 2006-12-06 2008-06-12 Smithkline Beecham Corporation Bicyclic compounds and use as antidiabetics

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070562A1 (en) * 2003-07-11 2005-03-31 Jones Robert M. Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2005121121A2 (en) * 2004-06-04 2005-12-22 Arena Pharmaceuticals, Inc. Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20080058339A1 (en) * 2006-08-30 2008-03-06 Biovitrum New compounds
WO2008070692A2 (en) * 2006-12-06 2008-06-12 Smithkline Beecham Corporation Bicyclic compounds and use as antidiabetics

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012462B2 (en) 2008-05-21 2015-04-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US8940748B2 (en) 2009-10-08 2015-01-27 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9428475B2 (en) 2009-10-08 2016-08-30 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use

Also Published As

Publication number Publication date
WO2010048149A2 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
WO2010048149A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
WO2010088518A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
WO2009117421A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
WO2008067219A3 (en) Quinazolinone modulators of tgr5
WO2008011560A3 (en) Benzothiophene inhibitors of rho kinase
HRP20130357T1 (en) Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010062863A3 (en) Compositions containing satiogens and methods of use
PL2118074T3 (en) Compounds for the prevention and treatment of cardiovascular diseases
WO2007104053A3 (en) 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
GB201108374D0 (en) Compositions and methods for the treatment of altered synuclein function
HK1146894A1 (en) Compositions and methods for treating diseases of the nail
WO2010032875A3 (en) Heterocyclic carboxamide compounds
WO2006084015A3 (en) Raf inhibitor compounds and methods
WO2010056754A3 (en) Inhibition of mammalian target of rapamycin
WO2008070129A3 (en) Compositions and methods for the treatment of inflammatory disease
AU2007243282A8 (en) Compositions and methods for the treatment of cardiovascular disease
PL3216457T3 (en) Compounds and methods for the prevention or treatment of restenosis
WO2006081516A3 (en) USE OF BAFF TO TREAT Th2-MEDIATED CONDITIONS
WO2010014739A3 (en) Heterocyclic modulators of tgr5
PL2234631T3 (en) Compounds and methods for the treatment of vascular disease
PT1828151E (en) Malonamide derivatives as inhibitors of gamma-secretase for the treatment of alzheimer`s disease
WO2007137098A3 (en) Sulfonyl-substituted bicyclic compounds as modulators of ppar
WO2010085799A9 (en) Compositions and method for the treatment of parkinson's disease
WO2010011684A3 (en) Prodrug and fluoregenic compositions and methods for using the same
GB0620695D0 (en) Composition and methods for the treatment of nurdegenerative disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09822536

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09822536

Country of ref document: EP

Kind code of ref document: A2